Here’s how to trade JNJ while consumers are concerned about the company’s Covid-19 booster shot results.
Johnson & Johnson JNJ set its all-time intraday high of $179.89 on August 20 on positive thoughts about its Covid-19 vaccine. Since then, consumers became concerned about the strength of the company’s booster shot. The vaccines available from Pfizer PFE and Moderno are deemed to be effective against the ferocious delta variant. Shares of JNJ fell so quickly that its weekly chart is now negative. The stock is reasonably priced with a p/e ratio of 18.83% with a dividend yield of 2.47%, according to Macrotrends. JNJ has beaten earnings-per-share estimates for at least 36 consecutive quarters.
